• Global Phase 3 clinical study completed
• Plan to file MA with FDA/EMA in 2024 H2
• Partner – Pharmapark (Russia and CIS countries)
Biological Drug Product, Formulation, mAb Formulation
Golimumab (Simponi®) biosimilar
Related products
-
FormulationCetrorelix Injection
-
Chemical Drug ProductTirzepatide Injection(multi-dose)(Mounjaro,Zepbound)
Indications:Glycemic Control,Weight Management
-
Biological Drug ProductSemaglutide Injection(Ozempic)
Indications:Glycemic Control
USA, EU, China approval single dose
-
Formulation
Sevoflurane Inhalation